

**TYK MEDICINES, INC / 浙江同源康醫藥股份有限公司**  
**ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT**  
**RESULTS**

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated 12 August 2024 (the “**Prospectus**”) issued by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”).

**Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.**

**SUMMARY**

**Company Information**

<b>Stock code</b>	2410
<b>Stock short name</b>	TYK MEDICINES-B
<b>Dealings commencement date</b>	20 August 2024*

\*see note at the end of the announcement

**Price Information**

<b>Final Offer Price</b>	HK\$12.100
<b>Offer Price Range</b>	HK\$12.100 - HK\$12.100
<b>Offer Price Adjustment exercised</b>	No

**Offer Shares and Share Capital**

<b>Number of Offer Shares</b>	47,880,000
<b>Number of Offer Shares in Public Offer (after reallocation)</b>	4,788,000
<b>Number of Offer Shares in International Offer (after reallocation)</b>	43,092,000
<b>Number of issued shares upon Listing</b>	370,835,818

**Offer Size Adjustment Option (Upsize option)**

<b>Number of additional shares issued under the option</b>	-
- <b>Public Offer</b>	-
- <b>International Offer</b>	-

**Over-allocation**

<b>No. of Offer Shares over-allocated</b>	-
---	---

**Proceeds**

<b>Gross proceeds (Note)</b>	HK\$ 579.35 million
<b>Less: Estimated listing expenses payable based on Final Offer Price</b>	HK\$ (73.04) million
<b>Net proceeds</b>	HK\$ 506.31 million

*Note: Gross proceeds refers to the amount to which the issuer is entitled receive. For details of the use of proceeds, please refer to the Prospectus.*

## ALLOTMENT RESULTS DETAILS

### HONG KONG PUBLIC OFFERING

<b>No. of valid applications</b>	974
<b>No. of successful applications</b>	649
<b>Subscription level</b>	2.29 times
<b>Re-allocation</b>	No
<b>No. of Offer Shares initially available under the Hong Kong Public Offering</b>	4,788,000
<b>No. of Offer Shares reallocated from the International Offering</b>	0
<b>Final no. of Offer Shares under the Public Offer (after reallocation)</b>	4,788,000
<b>% of Offer Shares under the Hong Kong Public Offering to the Global Offering</b>	10.00%

*Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to [www.eipo.com.hk/eIPOAllotment](http://www.eipo.com.hk/eIPOAllotment) to perform a search by name or identification number or [www.eipo.com.hk/eIPOAllotment](http://www.eipo.com.hk/eIPOAllotment) for the full list of allottees.*

### INTERNATIONAL OFFERING

<b>No. of places</b>	116
<b>Subscription Level</b>	1.01 times
<b>No. of Offer Shares initially available under the International Offering</b>	43,092,000
<b>No. of Offer Shares reallocated to the Hong Kong Public Offering</b>	0
<b>Final no. of Offer Shares under the International Offering (after reallocation)</b>	43,092,000
<b>% of Offer Shares under the International Offering to the Global Offering</b>	90.00%

*The Directors confirm that, to the best of their knowledge, information and belief, and save as the waiver and consent for Changxing Xingchang (as defined below) as a Cornerstone Investor granted by the Stock Exchange, (i) none of the Offer Shares subscribed by the places and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the places and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.*

The places in the International Offering include the following:

**Cornerstone Investor**

<b>Investor</b>	<b>No. of Offer Shares allocated</b>	<b>% of Offer Shares</b>	<b>% of total issued H Shares after the Global Offering</b>	<b>% of total issued share capital after the Global Offering</b>	<b>Existing shareholders or their close associates</b>
Changxing Xingchang Industrial Investment Partnership (Limited Partnership) / 長興興長產業投資合夥企業 (有限合夥) (“Changxing Xingchang”)	17,000,000	35.51%	8.83%	4.58%	Yes <sup>#</sup>
<b>Total</b>	<b>17,000,000</b>	<b>35.51%</b>	<b>8.83%</b>	<b>4.58%</b>	

**Allottee with waivers/consents obtained**

<b>Investor</b>	<b>No. of shares allocated</b>	<b>% of offer shares</b>	<b>% of total issued H Shares after the Global Offering</b>	<b>% of total issued share capital after the Global Offering</b>	<b>Relationship*</b>
Changxing Xingchang	17,000,000	35.51%	8.83%	4.58%	Core connected person
<b>Total</b>	<b>17,000,000</b>	<b>35.51%</b>	<b>8.83%</b>	<b>4.58%</b>	

<sup>#</sup> Please refer to the section headed “Others / Additional Information” in this announcement.

\*The Company has applied for, and the Stock Exchange has granted, a waiver from strict compliance with Rules 9.09(b) and 10.04 of the Listing Rules. The allocation of Offer Shares to Changxing Xingchang is in compliance with all the conditions under the consent granted by the Stock Exchange. Please refer to the “Waivers from Strict Compliance with Listing Rules and Exemption from Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance” section in the Prospectus for further details.

## LOCK-UP UNDERTAKINGS

### Controlling Shareholders

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Tetranov Pharmaceutical (Zhengzhou) Co., Ltd. / 鄭州泰基鴻諾醫藥股份有限公司 (“ <b>Tetranov Pharmaceutical</b> ”) <sup>Note 1</sup>	100,000,000 (including 35,000,000 H Shares and 65,000,000 Unlisted Shares)	18.17%	26.97%	19 August 2025 <sup>Note 3</sup>
Changxing Liyuan Enterprise Management Partnership (Limited Partnership) / 長興利源企業管理合夥企業(有限合夥) (“ <b>Changxing Liyuan</b> ”) <sup>Note 2</sup>	22,670,000 (including 7,934,500 H Shares and 14,735,500 Unlisted Shares)	4.12%	6.11%	19 August 2025 <sup>Note 3</sup>
Changxing Gangyuan Enterprise Management Partnership (Limited Partnership) / 長興罡源企業管理合夥企業(有限合夥) (“ <b>Changxing Gangyuan</b> ”) <sup>Note 2</sup>	4,800,000 (including 1,680,000 H Shares and 3,120,000 Unlisted Shares)	0.87%	1.29%	19 August 2025 <sup>Note 3</sup>

Changxing Caiyuan Enterprise Management Partnership (Limited Partnership) / 長興彩源企業管理合夥企業(有限合夥) (“Changxing Caiyuan”) <sup>Note 2</sup>	3,780,000 (including 1,323,000 H Shares and 2,457,000 Unlisted Shares)	0.69%	1.02%	19 August 2025 <sup>Note 3</sup>
Subtotal	131,250,000	23.85%	35.39%	

*Notes:*

(1) *Tetranov Pharmaceutical beneficially owns 35,000,000 H Shares and 65,000,000 Unlisted Shares. Tetranov Pharmaceutical is held as to approximately 30.66% by Dr. Wu, approximately 20.15% by Zhengzhou Hongnuo and approximately 3.02% by Zhengzhou Derui, respectively. Zhengzhou Hongnuo is managed by its executive partner, Huzhou Derui, which is owned as to 38.75% by Dr. Wu, 61% by Zhengzhou Derui and 0.25% by Mr. ZHANG Sen (張森), one of the Group’s employees. Zhengzhou Derui is wholly owned by Dr. Wu. As such, under the SFO, Dr. Wu is deemed to be interested in the 35,000,000 H Shares and 65,000,000 Unlisted Shares held by Tetranov Pharmaceutical. Ms. Zhu is spouse of Dr. Wu. Therefore, under the SFO, Ms. Zhu is deemed to be interested in the same number of Shares in which Dr. Wu is interested in.*

(2) *Changxing Liyuan beneficially owns 7,934,500 H Shares and 14,735,500 Unlisted Shares. Changxing Liyuan is managed by its executive partner, Zhengzhou Derui, which is wholly owned by Dr. Wu.*

*Each of Changxing Caiyuan and Changxing Gangyuan is the ESOP Platform. Changxing Caiyuan beneficially owns 1,323,000 H Shares and 2,457,000 Unlisted Shares. Changxing Gangyuan beneficially owns 1,680,000 H Shares and 3,120,000 Unlisted Shares. Each of Changxing Caiyuan and Changxing Gangyuan is managed by its executive partner, Huzhou Derui, which is owned as to 38.75% by Dr. Wu, 61% by Zhengzhou Derui and 0.25% by Mr. ZHANG Sen (張森), one of the Group’s employees. Zhengzhou Derui is wholly owned by Dr. Wu.*

*As such, under the SFO, Dr. Wu is deemed to be interested in (i) the 7,934,500 H Shares and 14,735,500 Unlisted Shares held by Changxing Liyuan; (ii) the 1,323,000 H Shares and 2,457,000 Unlisted Shares held by Changxing Caiyuan; and (iii) the 1,680,000 H Shares and 3,120,000 Unlisted Shares held by Changxing Gangyuan.*

(3) *The expiry date of the lock-up period shown in the table above is pursuant to the Hong Kong Underwriting Agreement and the applicable PRC laws.*

*Pre-IPO Investors (as defined in the “History, Development and Corporate Structure” section of the Prospectus)*

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Ningbo Meishan Bonded Port Area Houji Tongnuo Investment Management Partnership (Limited Partnership) / 寧波梅山保稅港區厚紀通諾投資管理合夥企業(有限合夥) (Houji Tongnuo) <sup>Note 1</sup>	14,146,619 (including 4,951,317 H Shares and 9,195,302 Unlisted Shares)	2.57%	3.81%	19 August 2025 <sup>Note 7</sup>
Changsanjiao Tengyuan (Changxing) Medical Equity Investment Partnership (Limited Partnership) / 長三角騰遠(長興)醫療股權投資合夥企業(有限合夥) (Changsanjiao Tengyuan)	12,600,000 (including 4,410,000 H Shares and 8,190,000 Unlisted Shares)	2.29%	3.40%	19 August 2025 <sup>Note 7</sup>
Changxing Guohai Donghu Equity Investment Partnership (Limited Partnership) / 長興國海東湖股權投資合夥企業(有限合夥) (Changxing Guohai) <sup>Notes 2 &amp; 6</sup>	12,185,600 (including 3,046,400 H Shares and 9,139,200 Unlisted Shares)	1.58%	3.29%	19 August 2025 <sup>Note 7</sup>
Sichuan Huiyu Pharmaceutical Co., Ltd. / 四川匯宇製藥股份有限公司 (Huiyu Pharmaceutical)	10,468,584 (including 3,664,004 H Shares and 6,804,580 Unlisted Shares)	1.90%	2.82%	19 August 2025 <sup>Note 7</sup>
Changxing Xingyin Equity Investment Partnership (Limited Partnership) / 長興興銀股權投資合夥企業(有限合夥) (Changxing Xingyin) <sup>Notes 3 &amp; 6</sup>	10,015,305 (including 3,505,357 H Shares and 6,509,948 Unlisted Shares)	1.82%	2.70%	19 August 2025 <sup>Note 7</sup>

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Jiangsu Addor Capital Results Innovation Venture Capital Fund (Limited Partnership) / 江蘇毅達成果創新創業投資基金(有限合夥) (Addor Results) <sup>Note 4</sup>	9,600,000 (H Shares)	4.98%	2.59%	19 August 2025 <sup>Note 7</sup>
Chengdu Boyuan Jiayu Venture Capital Partnership (Limited Partnership) / 成都博遠嘉昱創業投資合夥企業(有限合夥) (Chengdu Boyuan)	9,201,568 (including 3,220,549 H Shares and 5,981,019 Unlisted Shares)	1.67%	2.48%	19 August 2025 <sup>Note 7</sup>
Jiangsu Small and Medium Enterprises Development Fund (Limited Partnership) / 江蘇中小企業發展基金(有限合夥) (Jiangsu SME) <sup>Note 4</sup>	7,200,000 (H Shares)	3.74%	1.94%	19 August 2025 <sup>Note 7</sup>
Kunshan Huachuang Yida Biomedical Equity Investment Enterprise (Limited Partnership) / 昆山華創毅達生醫股權投資企業(有限合夥) (Huachuang Yida)	7,200,000 (H Shares)	3.74%	1.94%	19 August 2025 <sup>Note 7</sup>
Hangzhou Sanhua Hongdao Venture Capital Partnership (Limited Partnership) / 杭州三花弘道創業投資合夥企業(有限合夥) (Sanhua Hongdao)	7,200,000 (H Shares)	3.74%	1.94%	19 August 2025 <sup>Note 7</sup>

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Xiamen Ronghui Hongshang Equity Investment Partnership (Limited Partnership) / 廈門融匯弘上股權投資合夥企業(有限合夥) (Ronghui Hongshang)	7,200,000 (including 2,520,000 H Shares and 4,680,000 Unlisted Shares)	1.31%	1.94%	19 August 2025 <sup>Note 7</sup>
Ningbo Fuqi Venture Capital Partnership (Limited Partnership) / 寧波複祺創業投資合夥企業(有限合夥) (Fuqi Investment) <sup>Note 6</sup>	7,200,000 (including 2,520,000 H Shares and 4,680,000 Unlisted Shares)	1.31%	1.94%	19 August 2025 <sup>Note 7</sup>
Shenzhen Yangzi Xinkang Pharmaceutical Investment Enterprise (Limited Partnership) / 深圳揚子鑫康醫藥投資企業(有限合夥) (Yangzi Xinkang)	6,259,566 (including 2,190,848 H Shares and 4,068,178 Unlisted Shares)	1.14%	1.69%	19 August 2025 <sup>Note 7</sup>
Zhuzhou Guohai Guochuang Qianjin Pharmaceutical Venture Capital Partnership (Limited Partnership) / 株洲市國海國創千金醫藥創業投資合夥企業(有限合夥) (Guohai Guochuang) <sup>Note 2</sup>	6,144,000 (including 1,536,000 H Shares and 4,608,000 Unlisted Shares)	0.80%	1.66%	19 August 2025 <sup>Note 7</sup>
Zhuzhou Guochuang Junhe Investment Partnership (Limited Partnership) / 株洲市國創君和投資合夥企業(有限合夥) (Guochuang Junhe) <sup>Note 5</sup>	5,400,000 (including 1,890,000 H Shares and 3,510,000 Unlisted Shares)	0.98%	1.46%	19 August 2025 <sup>Note 7</sup>



<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Ningbo Meishan Bonded Port Area Houyang Tongchi Investment Management Partnership (Limited Partnership) / 寧波梅山保稅港區厚揚通馳投資管理合夥企業(有限合夥) (Houyang Tongchi) <sup>Note 1</sup>	5,258,035 (including 1,840,312 H Shares and 3,417,723 Unlisted Shares)	0.96%	1.42%	19 August 2025 <sup>Note 7</sup>
Huzhou Zhongjin Qihe Equity Investment Partnership (Limited Partnership) / 湖州中金啟合股權投資合夥企業(有限合夥) (CICC Qihe) <sup>Note 6</sup>	5,234,292 (H Shares)	2.72%	1.41%	19 August 2025 <sup>Note 7</sup>
Zhuzhou Wenzhou Junzhe Venture Capital Partnership (Limited Partnership) / 株洲市文周君喆創業投資合夥企業(有限合夥) (Wenzhou Junzhe) <sup>Note 5</sup>	5,120,000 (including 1,792,000 H Shares and 3,328,000 Unlisted Shares)	0.93%	1.38%	19 August 2025 <sup>Note 7</sup>
Zhejiang Silk Road Industrial Investment Fund Partnership (Limited Partnership) / 浙江絲路產業投資基金合夥企業(有限合夥) (Zhejiang Silk Road)	5,007,653 (H Shares)	2.60%	1.35%	19 August 2025 <sup>Note 7</sup>
Hunan Xiangyi Investment Tongyuan No. 1 Venture Capital Partnership (Limited Partnership) / 湖南湘醫投同源壹號創業投資合夥企業(有限合夥) (Hunan Xiangyi)	4,761,905 (including 1,666,667 H Shares and 3,095,238 Unlisted Shares)	0.87%	1.28%	19 August 2025 <sup>Note 7</sup>

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Hangzhou Qizhen Future Innovation Equity Investment Partnership (Limited Partnership) / 杭州啟真未來創新股權投資合夥企業(有限合夥) (Hangzhou Qizhen)	4,096,000 (H Shares)	2.13%	1.10%	19 August 2025 <sup>Note 7</sup>
Yangzhou Zekang Equity Investment Partnership (Limited Partnership) / 揚州澤康股權投資合夥企業(有限合夥) (Yangzhou Zekang)	3,655,575 (including 1,279,451 H Shares and 2,376,124 Unlisted Shares)	0.66%	0.99%	19 August 2025 <sup>Note 7</sup>
Jiangsu Talent Innovation Venture Capital Fund IV (Limited Partnership) / 江蘇人才創新創業投資四期基金(有限合夥) (Jiangsu Talent) <sup>Note 4</sup>	3,600,000 (H Shares)	1.87%	0.97%	19 August 2025 <sup>Note 7</sup>
Changxing Xinsheng Equity Investment Partnership (Limited Partnership) / 長興鑫晟股權投資合夥企業(有限合夥) (Changxing Xinsheng) <sup>Notes 3 &amp; 6</sup>	3,140,575 (including 1,099,201 H Shares and 2,041,374 Unlisted Shares)	0.57%	0.85%	19 August 2025 <sup>Note 7</sup>
Huzhou Haibang Shuhu Venture Capital Partnership (Limited Partnership) / 湖州海邦數湖創業投資合夥企業(有限合夥) (Haibang Shuhu) <sup>Note 6</sup>	3,072,000 (including 1,075,200 H Shares and 1,996,800 Unlisted Shares)	0.56%	0.83%	19 August 2025 <sup>Note 7</sup>

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Jiaxing Xingren Equity Investment Partnership (Limited Partnership) / 嘉興行仁股權投資合夥企業(有限合夥) (Jiaxing Xingren)	2,380,952 (including 833,333 H Shares and 1,547,619 Unlisted Shares)	0.43%	0.64%	19 August 2025 <sup>Note 7</sup>
Mr. JI Aining / 吉愛寧	2,380,000 (including 833,000 H Shares and 1,547,000 Unlisted Shares)	0.43%	0.64%	19 August 2025 <sup>Note 7</sup>
Jiaxing Wangying Shanghe Equity Investment Partnership (Limited Partnership) / 嘉興望盈上和股權投資合夥企業(有限合夥) (Wangying Shanghe) Note 6	1,884,160 (H Shares)	0.98%	0.51%	19 August 2025 <sup>Note 7</sup>
Shanghai Kaicheng Enterprise Management Consulting Partnership (Limited Partnership) / 上海凱乘企業管理諮詢合夥企業(有限合夥) (Shanghai Kaicheng)	720,000 (including 252,000 H Shares and 468,000 Unlisted Shares)	0.13%	0.19%	19 August 2025 <sup>Note 7</sup>
Shanghai Fanxi Enterprise Management Partnership (Limited Partnership) / 上海凡熹企業管理合夥企業(有限合夥) (Shanghai Fanxi) <sup>Note 5</sup>	600,000 (including 210,000 H Shares and 390,000 Unlisted Shares)	0.11%	0.16%	19 August 2025 <sup>Note 7</sup>
Huzhou Talent Innovation Equity Investment Fund Partnership (Limited	523,429 (H Shares)	0.27%	0.14%	19 August 2025 <sup>Note 7</sup>

<b>Name</b>	<b>Number of shares held in the Company subject to lock-up undertakings upon Listing</b>	<b>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</b>	<b>% of shareholding in the Company subject to lock-up undertakings upon Listing</b>	<b>Last day subject to the lock-up undertakings</b>
Partnership) / 湖州市人才創新股權投資基金合夥企業(有限合夥) (Huzhou Talent) <sup>Note 6</sup>				
Subtotal	183,455,818	49.79%	49.47%	

*Notes:*

- (1) Houji Tongnuo and Houyang Tongchi in aggregate will hold 19,404,654 Shares which represent approximately 5.23% of the total issued share capital of the Company upon Listing.
- (2) Changxing Guohai and Guohai Guochuang in aggregate will hold 18,329,600 Shares which represent approximately 4.94% of the total issued share capital of the Company upon Listing.
- (3) Changxing Xingyin and Changxing Xinsheng in aggregate will hold 13,155,880 Shares approximately 3.55% of the total issued share capital of the Company upon Listing.
- (4) Addor Results, Jiangsu SME and Jiangsu Talent in aggregate will hold 20,400,000 Shares which represent approximately 5.50% of the total issued share capital of the Company upon Listing.
- (5) Guochuang Junhe, Wenzhou Junzhe and Shanghai Fanxi in aggregate will hold 11,120,000 Shares which represent approximately 3.00% of the total issued share capital of the Company upon Listing.
- (6) More than 30% of the partnership interest of the relevant Shareholder is ultimately under the supervision and management of Zhejiang Provincial People's Government. Such relevant Shareholders under the supervision and management of Zhejiang Provincial People's Government will in aggregate hold 43,255,361 Shares which represent approximately 11.66% of the total issued share capital of the Company upon Listing, without taking into account the Shares to be subscribed by the cornerstone investor that is also ultimately under the supervision and management of Zhejiang Provincial People's Government, as further described in the section headed "Cornerstone Placing" in the Prospectus.
- (7) The expiry date of the lock-up period shown in the table above is pursuant to the applicable PRC laws.

**Existing Shareholder (other than the Pre-IPO Investors as defined in the “History, Development and Corporate Structure” section of the Prospectus)**

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Pivot Pharma Tech (Shanghai) Co., Ltd. / 貝沃特醫藥技術(上海)有限公司 (Pivot Pharma)	8,250,000 (including 2,887,500 H Shares and 5,362,500 Unlisted Shares)	1.50%	2.22%	19 August 2025
Subtotal	8,250,000	1.50%	2.22%	

*The expiry date of the lock-up period shown in the table above is pursuant to the applicable PRC laws.*

**Cornerstone Investor**

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i>
Changxing Xingchang	17,000,000 (H Shares)	8.83%	4.58%	19 February 2025
Subtotal	17,000,000	8.83%	4.58%	

*The Cornerstone Investor shall not dispose of any of the Offer Shares subscribed pursuant to the cornerstone investment agreement on or before the indicated date.*

***PLACEE CONCENTRATION ANALYSIS***

<b>Places<sup>(1)</sup></b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of Shares held upon Listing<sup>(2)</sup></b>	<b>% of total issued share capital upon Listing</b>
Top 1	17,000,000	39.45%	35.51%	60,255,361	16.25%
Top 5	34,103,500	79.14%	71.23%	77,358,861	20.86%
Top 10	41,036,500	95.23%	85.71%	84,291,861	22.73%
Top 25	43,046,500	99.89%	89.90%	86,301,861	23.27%

*Notes:*

*(1) Ranking of places is based on the number of H Shares allotted to the places.*

*(2) Number of Shares held upon Listing includes existing Shares.*

***H SHAREHOLDERS CONCENTRATION ANALYSIS***

<b>H Shareholders<sup>(1)</sup></b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of H Shares held upon Listing</b>	<b>% of total issued H Shares capital upon Listing</b>	<b>Number of Shares held upon Listing<sup>(2)</sup></b>
Top 1	0	0.00%	0.00%	45,937,500	23.85%	131,250,000
Top 5	17,000,000	39.45%	35.51%	116,625,539	60.56%	226,305,361
Top 10	29,113,500	67.56%	60.81%	144,948,321	75.26%	275,431,168
Top 25	39,406,500	91.45%	82.30%	182,194,340	94.60%	356,881,366

*Notes:*

*(1) Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.*

*(2) Number of Shares held upon Listing includes existing Shares.*

**SHAREHOLDER CONCENTRATION ANALYSIS**

<b>Shareholders<sup>(1)</sup></b>	<b>Number of H Shares allotted</b>	<b>Allotment as % of International Offering</b>	<b>Allotment as % of total Offer Shares</b>	<b>Number of Shares held upon Listing<sup>(2)</sup></b>	<b>% of total issued share capital upon Listing</b>
Top 1	0	0.00%	0.00%	131,250,000	35.39%
Top 5	17,000,000	39.45%	35.51%	243,910,015	65.77%
Top 10	17,000,000	39.45%	35.51%	290,150,167	78.24%
Top 25	36,543,500	84.80%	76.32%	358,779,318	96.75%

**Notes:**

*(1) Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.*

*(2) Number of Shares held upon Listing includes existing Shares.*



***BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING***

Subject to the satisfaction of the conditions set out in the Prospectus, 974 valid applications made by the public will be conditionally allocated on the basis set out below:

***Pool A:***

<b>NO. OF H SHARES APPLIED FOR</b>	<b>NO. OF VALID APPLICATIONS</b>	<b>BASIS OF ALLOTMENT/BALLOT</b>	<b>APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR</b>
500	614	294 out of 614 to receive 500 Shares	47.88%
1,000	117	112 out of 117 to receive 500 Shares	47.86%
1,500	37	500 Shares plus 16 out of 37 to receive additional 500 Shares	47.75%
2,000	36	500 Shares plus 32 out of 36 to receive additional 500 Shares	47.22%
2,500	18	1,000 Shares plus 6 out of 18 to receive additional 500 Shares	46.67%
3,000	19	1,000 Shares plus 15 out of 19 to receive additional 500 Shares	46.49%
3,500	8	1,500 Shares plus 2 out of 8 to receive additional 500 Shares	46.43%
4,000	20	1,500 Shares plus 14 out of 20 to receive additional 500 Shares	46.25%
4,500	1	2,000 Shares	44.44%
5,000	23	2,000 Shares plus 10 out of 23 to receive additional 500 Shares	44.35%
6,000	5	2,500 Shares plus 1 out of 5 to receive additional 500 Shares	43.33%
7,000	2	3,000 Shares	42.86%
8,000	7	3,000 Shares plus 5 out of 7 to receive additional 500 Shares	41.96%
9,000	7	3,500 Shares plus 2 out of 7 to receive additional 500 Shares	40.48%
10,000	18	4,000 Shares	40.00%

<b>NO. OF H SHARES APPLIED FOR</b>	<b>NO. OF VALID APPLICATIONS</b>	<b>BASIS OF ALLOTMENT/BALLOT</b>	<b>APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR</b>
15,000	3	6,000 Shares	40.00%
20,000	5	8,000 Shares	40.00%
25,000	3	10,000 Shares	40.00%
30,000	3	12,000 Shares	40.00%
50,000	3	20,000 Shares	40.00%
60,000	1	24,000 Shares	40.00%
70,000	1	28,000 Shares	40.00%
80,000	1	31,500 Shares	39.38%
90,000	1	35,000 Shares	38.89%
100,000	5	38,500 Shares	38.50%
200,000	4	76,500 Shares plus 3 out of 4 to receive additional 500 Shares	38.44%
300,000	5	115,000 Shares plus 3 out of 5 to receive additional 500 Shares	38.43%
400,000	3	153,500 Shares plus 1 out of 3 to receive additional 500 Shares	38.42%
Total	970	<b>Total number of Pool A successful applicants: 645</b>	

Pool B

NO. OF H SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF H SHARES APPLIED FOR
500,000	1	240,000 Shares	48.00%
1,250,000	1	598,500 Shares	47.88%
1,500,000	1	718,000 Shares	47.87%
1,750,000	1	837,500 Shares	47.86%
Total	4	<b>Total number of Pool B successful applicants: 4</b>	

*As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.*

**COMPLIANCE WITH LISTING RULES AND GUIDANCE**

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the places or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and trading fee payable.

**OTHERS / ADDITIONAL INFORMATION**

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a waiver and consent under Rule 9.09(b) and Rule 10.04 of the Listing Rules and Paragraph 5(2) of the Placing Guidelines allow Changxing Xingchang to subscribe for H Shares as Cornerstone Investor in the Global Offering. As more than 30% of the partnership interest of each of Huzhou Talent, Changxing Xingyin, Changxing Xinsheng, CICC Qihe, Changxing Guohai, Haibang Shuhu, Wangying Shanghe and Fuqi Investment (the existing Shareholders, collectively, the “**Zhejiang-related Entities**”) are ultimately under the supervision and management of Zhejiang Provincial People’s Government, and the Zhejiang-related Entities will in aggregate hold 43,255,361 Shares which represent approximately 11.66% of the total issued share capital of the Company upon Listing, they are regarded as core connected persons of the Company. Changxing Xingchang is an entity under the supervision and management of Changxing County People’s Government which is a county government in Zhejiang province. For the details, please refer to the section headed “Waivers from Strict Compliance with Listing Rules and Exemption from Strict Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance – Cornerstone Subscription by Core Connected Person During the Listing Application Process”.

## **DISCLAIMERS**

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated 12 August 2024 issued by TYK Medicines, Inc for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.*

*Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – 2. Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on 20 August 2024).*

## **PUBLIC FLOAT**

Immediately following completion of the Global Offering, (i) taking into account the Conversion of 144,706,173 Unlisted Shares into H Shares to be issued and held by the Pre-IPO Investors and existing Shareholders, 93,007,501 H Shares, representing 25.08% of the total issued Shares will be held in the public hands, satisfying the minimum percentage requirement under Rule 8.08(1) of the Listing Rules; (ii) the three largest public Shareholders will not hold more than 50% of the Shares held in the public hands at the time of Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iii) there will be at least 300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.

The Directors confirm that immediately after the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company; and (ii) there will not be any new substantial shareholder (as defined in the Listing Rules) of the Company.

## **COMMENCEMENT OF DEALINGS**

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, 20 August 2024 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in “Underwriting — 2. Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. on Tuesday, 20 August 2024 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, 20 August 2024 (Hong Kong time). The H Shares will be traded in board lots of 500 H Shares each, and the stock code of the H Shares will be 2410.

By order of the Board  
**TYK Medicines, Inc**  
(浙江同源康醫藥股份有限公司)

**Dr. WU Yusheng**  
*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, 19 August 2024

*As of the date of this announcement, the executive Directors are Dr. WU Yusheng and Dr. JIANG Mingyu, the non-executive Directors are Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying, Mr. HE Chao and Dr. DING Zhao, and the independent non-executive Directors are Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua.*